Last updated: July 14, 2026
- Case: Salix Pharmaceuticals, Inc. v. Amneal Pharmaceuticals of New York, LLC, 1:24-cv-04607 (D.N.J.).
- Docket year: 2024.
- Litigation posture and patent-specific merits: Not provided in the input. Without the complaint, asserted patent list, ANDA number(s), Orange Book listing, or claim/construction record, no accurate litigation summary (issues, deadlines, requested injunction scope) can be produced.
SALIX PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS OF NEW YORK, LLC (1:24-cv-04607): Litigation summary, asserted patents, and outcome
What patents are asserted in SALIX v. AMNEAL 1:24-cv-04607?
No patent numbers, Orange Book identifiers, or asserted claims were included in the provided information. A litigation summary that names the asserted patents, links them to the specific drug/NDC, and maps the alleged infringement to the claim language cannot be constructed from the docket identifier alone.
What is the relevant drug product and ANDA number tied to the dispute?
The drug, strength, dosage form, and ANDA application number are not included. Those inputs are required to anchor an Orange Book and infringement analysis.
What is the procedural timeline for SALIX v. AMNEAL 1:24-cv-04607?
No filings (complaint date, TRO/preliminary injunction motion, Amneal’s answer, Rule 12 motions, claim construction orders, scheduling order) are included. A timeline with dates and event sequence cannot be produced.
Has there been an injunction or TRO in 1:24-cv-04607?
The record of any temporary restraining order, preliminary injunction motion, or consent stay is not provided. This prevents a credible statement of litigation posture.
Are there claim construction, summary judgment, or trial dates set?
No claim construction schedule or dispositive motion outcomes were provided. Without them, any statement about Markman, summary judgment, or trial posture would be unsupported.
What is the Paragraph IV landscape for this SALIX v. AMNEAL case?
The input does not include the Paragraph IV certifications, the Orange Book patents identified in the ANDA, or the timing of any FDA FDA 30-month stay.
Does the case challenge Orange Book-listed patents for brand exclusivity?
The asserted patent coverage list (method-of-use, formulation, polymorph, manufacturing, or secondary-use) is not provided, so the exclusivity and scope cannot be analyzed.
How strong is the patent estate in SALIX v. AMNEAL 1:24-cv-04607?
Patent strength analysis requires at least:
- asserted patent numbers and expiration dates,
- prosecution history or reexamination,
- invalidity grounds (35 U.S.C. §§ 102/103/112) asserted by Amneal,
- and any adjudicated rulings.
None of these inputs appear in the provided information.
What invalidity defenses (102, 103, 112, inequitable conduct) are raised?
No invalidity allegations were included. A litigation analysis cannot quantify or classify likely defenses without the actual pleadings.
What design-around arguments are claimed by Amneal?
No product composition, process, or specification-level differences were provided.
What does SALIX claim about infringement in 1:24-cv-04607?
An infringement summary requires the asserted claim set and the alleged mapping to the accused product. Those details are missing.
Is infringement alleged under product-by-process, composition, or method-of-use claims?
No asserted claim type information was provided.
What evidence is typically cited (lab testing, bioequivalence batches, documents discovery)?
No discovery record or evidence references were included.
What settlements or agreed remedies exist for SALIX v. AMNEAL 1:24-cv-04607?
No settlement terms, consent judgments, or standstill agreements were provided.
Did the parties enter a stipulated dismissal or licensing arrangement?
No procedural disposition or license terms were included.
What is the FDA regulatory status tied to this litigation?
A litigation analysis often ties pleadings to:
- ANDA status,
- tentative approval dates,
- FDA acceptance/rejection,
- 30-month stay,
- and eventual generic launch.
None of those data points are in the input.
What is the Orange Book status of the patents at issue?
Orange Book listings and statuses (listed for particular NDCs/strengths and patent types) are not provided.
How does SALIX’s litigation position compare with other SALIX vs. ANDA cases?
No data was provided about other matters, consolidated dockets, or brand portfolio enforcement strategy.
What generic entry risks exist for Amneal or other filers tied to this dispute?
Entry risk analysis requires the 30-month stay posture, injunction status, and the remaining claim/patent barriers. None of that is included.
What manufacturing and IP barriers are raised in the pleadings?
No technical manufacturing allegations were included.
Where is the case being litigated (court, jurisdiction, venue) and what does that imply procedurally?
The case number implies federal district litigation, but the specific court division, judge, and assigned magistrate are not included. Procedural implications cannot be stated accurately without the assignment details.
Key Takeaways
- The docket identifier 1:24-cv-04607 alone is insufficient to produce a litigation summary with asserted patents, procedural milestones, infringement/invalidity contentions, or remedies.
- No Orange Book, ANDA, Paragraph IV, or settlement/injunction facts were provided, so no defensible analysis can be generated from the input.
FAQs
- What is the typical pleading structure for a Salix Orange Book patent case against an ANDA filer, and what should be checked first?
- How do Paragraph IV certifications drive the 30-month stay and how does that affect litigation leverage?
- What claim types (method-of-use vs formulation) most commonly control infringement outcomes in Salix-related disputes?
- What procedural events most often change case value in Hatch-Waxman litigation (Markman, Daubert, summary judgment, injunction motions)?
- How do claim-scope rulings usually map to design-around strategies for generic manufacturers?
References (APA)
- United States District Court, District of New Jersey. Salix Pharmaceuticals, Inc. v. Amneal Pharmaceuticals of New York, LLC, Case No. 1:24-cv-04607.
